Print Plan Forms |

Drug Safety Alerts

Tanzeum® Discontinuation

7/26/18

On July 26, 2017, GSK announced that after 3 years of providing Tanzeum^® (albiglutide) (30 mg and 50 mg for injection) as a treatment option for adults with type 2 diabetes mellitus, GSK has made the difficult decision to discontinue the commercial sale of Tanzeum.

GSK’s decision is not related to any known safety concern. GSK reports that they dedicated significant effort to educating health care providers on the safety and efficacy profile of Tanzeum for appropriate patients. However, even with this support, GSK reports that there has been limited prescribing of the medicine and, given the range of alternative treatments available, it has become harder and harder to have the impact on patients that GSK expected.

A completed list of products affected by this issue is available here:

GSK expects that commercial supply will be depleted by May 2018. GSK is notifying health care providers now to ensure they have sufficient time to transition any existing patients taking Tanzeum to an alternative therapy.

CVS/caremark Response: CVS Caremark will continue to dispense Tanzeum until current supplies are depleted at which time, patients will need a new prescription for an alternate medicine to treat their condition. CVS Caremark Mail Service Pharmacy is sending notification mailings to patients that received Tanzeum to advise them of this issue and their prescribers.

For more information on this issue, health care providers may contact GSK Customer Response Center at 1-888-825-5249 or visit https://www.tanzeum.com/

You may also contact the U.S. Food and Drug Administration (FDA) consumer inquiry line at 1‑888-INFO-FDA (1-888-463-6332) or by accessing their Web site at https://www.fda.gov.

Drug Safety Alerts

Tanzeum® Discontinuation

Health Resources

Corporate Information

For Employers, Pharmacists & Medical Plan Providers

Need Help?